Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

The application of prostate-specific antigen (PSA) in prostate cancer (PC) screening,
diagnosis, and prognosis has improved the clinical management of PC patients. However …

Prostate cancer (PCa) is the most commonly diagnosed male cancer in the United States.
The prostate-specific antigen (PSA) biomarker has been widely used to screen men for …

The widespread use of the PSA test has led to increased detection of the disease at earlier
stages and a reduction in the number of patients where metastatic disease is found at …

INTRODUCTION: Due to its universal applicability for early detection and prediction of
cancer stage and disease recurrence, widespread implementation of serum-based prostate …

The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication
have revolutionized the diagnosis and management of the disease. Current clinical practice …

The increased incidence and the significant health burden associated with carcinoma of the
prostate have led to substantial changes in its diagnosis over the past century. Despite …

PURPOSE: The limitations of prostate specific antigen as a biomarker for prostate cancer
screening, characterized by low sensitivity for acceptable false-positive rates, are well …